Laquinimod Disappoints Again, This Time In Huntington's Disease
Laquinimod fails to impress in a Phase II study in Huntington's disease, adding to a series of clinical trial setbacks over past years for the potential oral immunomodulator.
Laquinimod fails to impress in a Phase II study in Huntington's disease, adding to a series of clinical trial setbacks over past years for the potential oral immunomodulator.